What question did this study set out to answer?

February 19, 2026Clinical Cancer Research

Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

View Full Paper

Ask AI

Bookmark

Authors

CDC. DenkertPhilipps University of Marburg SRSivaramakrishna RachakondaGerman Breast group TKThomas KarnGoethe University Frankfurt

Discussion

Member takes

Implication

This analysis reveals gene expression subtypes predict response to neoadjuvant immune-chemotherapy in triple-negative breast cancer, suggesting implications for treatment strategies.

Key Points

To evaluate gene expression subtyping of early triple-negative breast cancer (TNBC) for predicting responses to neoadjuvant immune-chemotherapy.
Analyzed 494 pre-therapeutic biopsies for 2549 genes using the HTG EdgeSeq system.
Employed classical AIMS and TNBC subtyping methods.
Endpoints included pathological complete response (pCR) and event-free survival (EFS).
Assessed predefined gene expression signatures focusing on immune, proliferation, and stromal genes.
Classical AIMS subtyping identified 70.5% Basal-like and 23.8% HER2-enriched subtypes.
TNBC subcategories included immunomodulatory (25.5%) and Mesenchymal (23.9%).
pCR rates varied by subtype, with IM subtype achieving 74.6% pCR.
Significant immune gene expression correlated with pCR and EFS in treated patients.

Cite This Study

Denkert et al. (2026) studied this question.

synapsesocial.com/papers/6996a869ecb39a600b3ef1e3 https://doi.org/10.1158/1557-3265.sabcs25-rf3-02

View Full Paper

Ask AI

Bookmark

Implication

This analysis reveals gene expression subtypes predict response to neoadjuvant immune-chemotherapy in triple-negative breast cancer, suggesting implications for treatment strategies.

Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract RF3-02: Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer (TNBC) for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider